Alexion (AstraZeneca) and Neurimmune Expand Alliance to Develop NI009 for AL Amyloidosis

Shots: Neurimmune has entered into an exclusive global collaboration & licensing deal with Alexion to develop NI009, a preclinical human mAb for the treatment of AL amyloidosis Alexion will obtain an exclusive global license to Neurimmune’s AL amyloidosis–targeting Abs, incl. NI009, with Neurimmune handling preclinical activities, early manufacturing & the FIH study, while Alexion will…

ByRidhi Rastogi2 days ago

NEWS

Alexion Partners with JCR Pharmaceuticals to Develop Genomic Medicines

Shots: JCR Pharmaceuticals & Alexion have entered into a license agreement for JCR’s JUST-AAV capsids to develop genomic medicines As per the deal, Alexion may use licensed capsids from the JUST-AAV platform in up to 5 genomic medicine programs in exchange for an undisclosed upfront payment, ~$225M in R&D milestones, ~$600M in sales milestones (milestones…

ByRidhi RastogiJuly 9, 2025

TOP 20

Top 20 BioPharma Companies based on 2020 Total Revenue

Despite having the global Covid-19 pandemic- the biopharma companies were involved in multiple M&A and licensing deals. The major focus of the year remains the production and distribution of vaccines to combat the COVID-19 globally All of the Biopharma companies on our list are on the front line to combat this global crisis. The top…

ByPrince GiriApril 8, 2021

TOP 20

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

The biopharma industry saw numerous deal terminations in 2020. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. Sanofi and Hanmi's agreement in 2015 ranked first under which Hanmi regained WW rights to its protein/peptide discovery technology- lapscovery. The second position goes to the…

ByPrince GiriFebruary 11, 2021

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2020

The second quarter of 2020 has ended with big approvals in pharma and biotech industry. Moving with the latest approval of Roche's Phesgo and Enspryng & Zogenix's Fintepla. Highlights of the quarter is COVID-19 as the development of vaccines and drugs were on peak. Celltrion evaluated Remsima (biosimilar, infliximab) against COVID-19 in the UK. The…

BySenior EditorJuly 7, 2020

INSIGHTS+

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days are included. Our PharmaShots team summarized the key deals which were presented during the updates from companies from Jan 13 to Jan 16, 2020. Date…

BySenior EditorFebruary 7, 2020

TOP 20

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology- neuroscience- oncology- rare diseases- and plasma-derived therapies. This article is based on the 2018…

ByPrince GiriSeptember 27, 2019

Alexion (AstraZeneca) and Neurimmune Expand Alliance to Develop NI009 for AL Amyloidosis

Alexion Partners with JCR Pharmaceuticals to Develop Genomic Medicines

Top 20 BioPharma Companies based on 2020 Total Revenue

Top 20 Biopharma Deal Terminations of 2020 Based on Total Deal Value

PharmaShots’ Key Highlights of Second Quarter 2020

Insights+: Key Deals of J.P. Morgan Healthcare Conference 2020

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

Contact US

OUR INFORMATION

FOLLOW US